Role of chemically modified tetracycline on TNF-α and mitogen-activated protein kinases in sepsis

Shock

Volumn 22, Issue 5, 2004, Pages 478-481

  Maitra, Subir R ^a,b   Bhaduri, Sikha ^a   Chen, Elliott ^a   Shapiro, Marc J ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CLP; CMT 3; MAPK; p38; p42 44; Rat; SAPK JNK

Indexed keywords

CHEMICALLY MODIFIED TETRACYCLINE 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P42; PROTEIN P44; SODIUM CHLORIDE; STRESS ACTIVATED PROTEIN KINASE; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; EXPERIMENTAL MODEL; LIVER LEVEL; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN INDUCTION; RAT; SEPSIS; SEPTIC SHOCK; TECHNIQUE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; LIVER; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; TETRACYCLINE; TETRACYCLINES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8144226374     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000140298.40440.51     Document Type: Article

References (42)

1. Maitra SR, Homan C, Beuhler M, Thode H, Henry MC: Alterations in hepatic gluconeogenesis, prostanoid and intracellular calcium during sepsis. Acad Emerg Med 6:588-595, 1999.
2. Maitra SR, Wojner M, Lang C: Alterations in tissue glucose uptake during the hyperglycemic and hypoglycemic phases of sepsis. Shock 13:379-385, 2000.
3. Maitra SR, Wang S, El-Maghrabi MR: Glucose-6-phosphatase gene expression in sepsis. J Trauma 49:38-42, 2000.
4. Maitra SR, Chen E, Rosa D, Valane PD, El-Maghrabi MR, Brathwaite CEM: Modulations of signal transduction pathways during sepsis and the effects of insulin and Mifepristone. Acad Emerg Med 10:1-8, 2003.
5. Maitra SR, Bhaduri S, Valane P, Tervahartiala T, Sorsa T, Ramamurthy N: Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock 20:280-285, 2003.
6. Wichler S, Cuvelier SL, Chakrabooti S, Patel K: P38 MAP Kinase regulates rapid matrix metalloproteinase-9 release from eosinophils. Biochem Biophys Res Commun 315:463-470, 2004.
7. Oberholzer A, Oberholzer C, Moldawer LL: Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16:83-96, 2001.
8. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis 161:982-987, 1990.
9. Drost AC, Burleson DG, Cioffi WG, Jordan BS, Mason AD, Pruitt BA: Plasma cytokines following thermal injury and their relationship with patient mortality, burn size and time post burn. J Trauma 35:335-339, 1993.
10. Casey LC, Balk RTA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771-778, 1993.
11. Abraham E: Clinical sepsis trials. Chest 105:535-555, 1994.
12. Fisher CJ, Opal SM, Lowry SF, Sadoff JC, LaBrecque JF, Donovan HC, Lookabaugh JL, Lemke J, Pribble JP, Stromatt SC, Vigers GP, Russell DA, Thompson RC: Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. Circ Shock 44:1-8, 1994.
13. Lee SH, Yune TY, Kim SJ, Park W, Lee YK, Kim YC, Oh YJ, Markelonis G, Oh T: Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 20:1017-1027, 2003.
14. Zhu S, Stravrovskaya I, Drozda M, Kim BYS, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu du C, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochrome with release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417:74-78, 2002.
15. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T: Tetracycline inhibits connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12:12-26, 1998.
16. Mitscher LA: The Chemistry of Tetracyclines, Vol. 1. New York: Marcel Dekker, 1978, pp 72-180.
17. Chen J, Bookbinder M, Ryan ME, Golub LM, Ashley R, Ramamurthy NS: Biodistribution of radiolabelled 3H/CMT-3 in rats. Curr Med Chem 8:253-256, 2001.
18. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25:1095-1100, 1997.
19. Bernard GR: Sepsis trials. Intersection of investigation, regulation, funding, and practice. Am J Respir Crit Care Med 152:4-10, 1995.
20. Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA: Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 120:574-588, 1992.
21. Nieman GF, Zerler BR: A role for the anti-inflammatory properties of tetracyclines in the prevention of acute lung injury. Curr Med Chem 8:317-325, 2001.
22. Shapira L, Soskolne WA, Houri Y, Barak V, Halabi A, Stabholz A: Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun 64:825-828, 1996.
23. Mohler KM, Sleuch PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torranee DS, Otten-Evans C, Greenstreet T, Weerawarna K, Kronheim SR, Petersen M, Gerhan M, Kozlosky CJ, March CJ, Black RA: Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370:218-220, 1994.
24. Solorzano CC, Ksontini R, Pruitt JH, Auffenberg T, Tannahil C, Galardy RE, Schultz GP, MacKay SLD, Copeland EM III, Moldawer LL: A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock 7:427-431, 1997.
25. Ramamurthy N, Rifkin B, Greenwald R, Xu J, Liu Y, Turner G, Golub L, Vernillo A: Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: A comparison of 6 chemically modified tetracyclines. J Periodontol 73:726-734, 2002.
26. D'Agostino P, Ferlazzo V, Milano S, La Rosa M, Di Bella G, Caruso R, Barbera C, Grimaudo S, Tolomeo M, Feo S, Cillari E: Anti-inflammatory effects of chemically modified tetracyclines by the inhibition of nitric oxide and interlukin-12 synthesis in J775 cell line. Int Immunopharmacol 1:1765-1776, 2001.
27. Barone FC, Irving EA, Ray AM: Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med Res Rev 21:129-145, 2001.
28. Lee JC, Laydon JT, McDonnel PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Keys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-744, 1994.
29. Brook M, Sully G. Clark AR, Saklatvala J: Regulation of tumor necrosis factor alpha mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. FEBS Lett 483:57-61, 2000.
30. DeAlvaro C, Teruel P, Hernandez R, et al.: Tumor necrosis factor-alpha produces insulin resistance in skeletal muscle by activation of inhibitor KB kinase in a p38 mitogen-activated protein kinase-dependent maner. J Biol Chem (in press).
31. Gustin J, Pincheira R, Mayo LD, Ozes ON, Kessler KM, Faerwald MR, Korgaonkar CK, Donner DB: Tumor necrosis factor activates CRE-binding protein through a p38 MApK/MSK1 signaling pathway in endothelial cells. Am J Physiol Cell Physiol 286:C547-C555, 2004.
32. Valladares A, Alvarez A, Ventura J, Roncero C, Benito M, Porras A: P38 mitogen-activated protein kinase mediates tumor necrosis factor-alpha-induced apoptosis in rat fetal brown adipocytes. Endocrinology 141:4383-4395, 2000.
33. Chen XL, Xia ZF, Wei D, Man S, Ben DF, Wang GD. Role of mitogen-activated protein kinase in Kupffer cell secretion of the proinflammatory cytokines after burn. Burns 29:533-539, 2003.
34. Song GY, Chung CS, Jarrar D, Chaudry IH, Ayala A: Evolution of an immune suppressive macrophage phenotype as a product of p38 MAPK activation in polymicrobial sepsis. Shock 15:42-48, 2001.
35. Jiang JX, Zhang Y, Ji SH, Zhu P, Wang ZG: Kinetics of mitogen-activated protein kinase family in LPS stimulated mouse Kupffer cells and their role in cytokine production. Shock 18:336-341, 2002.
36. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DLG, Luecke S, Phebus LA, Bymaster FP, Paul SM: Minocycline prevents nigrostriated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98:14669-14674, 2001.
37. Scougall KT, Shaw JA: Tetracycline-regulated secretion of human insulin in transfected primary myoblasts. Biochem Biophys Res Commun 304:167-175, 2003.
38. Callejas NA, Casado M, Diaz-Guerra MJ, Bosca L, Martin-Sauz P: Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 33:860-867, 2001.
39. Moon SK, Cha BY, Kim CH: ERK 1/2 mediates TNF-alpha-indueed matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: Involvement of the res dependent pathway. J Cell Physiol 198:417-427, 2004.
40. Fingleton B: CMT-2. CollaGenex. Curr Opin Investig Drugs 4:1460-1467, 2003.
41. Steinberg J, Halter J, Schiller HJ, Dasilva M, Landas S, Gatto LA, Maisi P, Sorsa T, Rajamaki M, Lee H-M, Nieman GF: Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J Surg Res 111:185-195, 2003.
42. Lalu M, Gao C, Schulz R: Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9. Mol Cell Biochem 251:61-66, 2003.